KENYA BLAKE CODRINGTON: Open Payments
NPI 1750940466 · LAUREL, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$576 in 10 payments from 9 companies in 2025. Trend: 2023 $542 · 2024 $954 · 2025 $576
Food & beverage: $400Education: $176
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $176 |
| Janssen Biotech, Inc. | 1 | $132 |
| Merck Sharp & Dohme LLC | 1 | $122 |
| Exelixis Inc. | 1 | $31 |
| E.R. Squibb & Sons, L.L.C. | 1 | $28 |
| Lilly USA, LLC | 1 | $26 |
| ABBVIE INC. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: RYBREVANT, KEYTRUDA, CABOMETYX, OPDIVO, VERZENIO, BOTOX, GEMTESA, CAPLYTA.
Industry payments across MD — which companies pay providers there.
